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Abstract
Background: Patients with schizophrenia have the highest known rates of cigarette smoking, but less is known
about their smoking behavior and the differences across geographical regions, including Croatia.
The aim of this study was to compare patterns of nicotine dependence between patients with schizophrenia and
healthy individuals, and to determine the relationship between clinical presentation and the severity of smoking.
Methods: This cross-sectional study included 182 recently hospitalized male inpatients and 280 healthy males, who
were daily smokers. All participants have fulfilled the Fagerstrom Test for Nicotine Dependence (FTND). Patients
were also evaluated by the Positive and Negative Syndrome Scale (PANSS).
Results: Patients had higher FTND total score (p = 0.010), smoked their first cigarette earlier in the morning (p = 0.
000), consumed higher number of cigarettes (p = 0.000), while healthy subjects had more difficulties to refrain from
smoking in places where it is forbidden (p = 0.000) and smoked more even when they were sick (p = 0.000). While
severe dependence was more prevalent in the patient group, light dependence was more frequent in control
subjects (p = 0.04). Smoking behavior was not associated with either PANSS total score or any of its subscales and
items.
Conclusions: Smokers with schizophrenia differ from healthy smokers in both smoking behavior and level of
dependence. Longitudinal studies are needed to shed more light on the complex relationship between smoking
and psychopathology in schizophrenia.
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Background
Smoking is one of the largest risk-factors for prema-
ture mortality from non-communicable diseases in
general population [1]. Patients with schizophrenia
have the highest known rates of cigarette smoking
and it was consistently reported in different parts of
the world [2–6]. Such high prevalence of smoking
contributes to premature mortality in those patients,
which does not lessen over time [7]. Men appear to
be even at higher risk for those unfortunate findings
compared to women [1, 7].
However, less is known whether the level of nicotine
dependence differs in smokers with schizophrenia com-
pared to healthy individuals, and how smoking interacts
with symptoms of the disease. For example, among
smokers who smoked at least 20 cigarettes per day, and
had similar levels of nicotine dependence, those with
schizophrenia or schizoaffective disorder had higher
number of puffs smoked per cigarette, larger cigarette
total puff volume, shorter inter-puff interval duration as
well as higher carbon monoxide boosts, compared to
participants who had no major mental illness [8]. Simi-
larly, smokers with schizophrenia had higher four-
minute nicotine boost and a higher dose of nicotine per
cigarette than persons without mental illness in the pre-
vious year [9]. Moreover, male patients with schizophre-
nia had higher proportion of smoking more than 10
cigarettes daily, and lower proportion of individuals who
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stopped smoking [10] compared to males with negative
history for psychiatric disorders. The relationship be-
tween illness severity and smoking indices is incom-
pletely understood. Previous studies have reported
mixed results on the association between smoking and
the intensity of symptoms. While majority of studies
suggested that smokers with schizophrenia had more se-
vere symptoms [10–15], one study reported similar over-
all symptomatology [15], while a series of studies
reported milder symptoms in smokers than in non-
smokers [16–18]. In patients with first-episode schizo-
phrenia, smokers had higher positive and negative
syndrome scale (PANSS) total score and PANSS positive
subscale scores and similar PANSS negative and PANSS
general scores, in comparison to patients who were non-
smokers [10]. Among patients with several psychiatric
disorders, including schizophrenia, smokers were more
likely than nonsmokers to report hallucinations, delusions
and subjective thought disorder and had worse negative
symptoms [11]. In patients with schizophrenia, smokers
with severe nicotine dependence had greater PANSS
positive, while smokers with mild nicotine dependence
had higher PANSS negative scores, respectively, compared
to patients who did not smoke [12]. In another study on
patients with schizophrenia, smokers had higher PANSS
positive score than nonsmokers, while tobacco smoking
was associated with more positive symptomatology, and
less negative symptoms. [13]. Moreover, PANSS total
scores and the PANSS general psychopathology scores
were higher in non-smokers compared to smokers while
PANSS positive and negative scores were similar between
smokers and non-smokers with schizophrenia [14]. In pa-
tients with treatment-resistant schizophrenia (TRS),
smokers had higher PANSS total score and PANSS nega-
tive score than nonsmokers, while there were no differ-
ences in two groups in PANSS positive and general scores
[15]. Smoking status was not associated with PANSS total
score in a sample consisted of patients with schizophrenia
and bipolar disorder, although no data on PANSS sub-
scales were presented [5]. On the opposite, in male inpa-
tients with schizophrenia, smokers had lower PANSS
positive scores, with no differences in the PANSS total
score or the negative and general psychopathology
subscales compared with non-smokers [16]. Notably, in
this study, smokers who smoked more cigarettes had
lower intensity of negative symptoms [16]. In the two
studies on male patients with schizophrenia, current
smokers had lower PANSS negative scores than never
smokers [17] and never smokers and former smokers [18].
The discrepancies across those studies might arise from
many methodological issues, such as different measures of
psychopathology, sample sizes, age and sex differences,
study settings (outpatients versus inpatients) and the
presence of comorbid substance abuse. For example,
psychopathology was estimated by The Diagnostic
Interview for Psychosis [11] and PANSS total score and its
subscales [10] as well as only PANSS total score [5]. Of
note, smokers with schizophrenia have also received
higher daily doses of antipsychotics [12, 14] than non-
smokers. While larger doses are logically related to higher
severity of symptoms, they could also result from
smoking-induced hepatic metabolism of some antipsy-
chotics, such as clozapine and olanzapine [19]. Interest-
ingly, in the sample of patients with TRS, smokers and
nonsmokers did not differ in terms of mean daily anti-
psychotic dose [15]. Majority of those studies analyzed the
association of smoking versus non-smoking status with
psychopathology [5, 10, 11, 14, 15, 13], while few have in-
vestigated the influence of severity of nicotine dependence
on psychopathology [16].
The relationship between schizophrenia and nicotine
dependence is complex [20] and includes some shared
genetic vulnerability [21]. Reasons for such high preva-
lence of cigarette smoking in patients with schizophrenia
are still unclear [20]. So far, dopamine appears to play a
major role in this relationship. It is well-known that
schizophrenia is linked to elevated dopamine levels in
dorsal striatum and reduced cortical dopamine release
[reviewed in [22]. Nicotine increases dopamine levels in
striatum by stimulating its release via nicotinic recep-
tors, and decreasing its degradation by inhibiting
monoamine oxidase type A and B. [reviewed in [20].
Clinical consequences include behavioral stimulation,
antidepressant effects and decrease of drug-induced
extrapyramidal adverse events [reviewed in [20]. More
recently, it has been reported that smoking also induced
cortical dopamine release, at least in subjects who
smoked ≥10 cigarettes daily and had no current psychi-
atric disorder [23].
There are differences across countries in both smoking
prevalence and smoking behavior in general population
[24], schizophrenic patients [25] and control samples
[2]. For example, smoking prevalence in general popula-
tion varied significantly across 18 European countries,
ranging from 40.9% in Bulgaria to 16.3% in Sweden [26].
In Croatian general population the rate of current smok-
ing was 26.6%, which was similar to European average of
27% [26] and to frequency of smoking in other European
transitional countries [27].
Interestingly, smokers in countries with lower smoking
prevalence such as Sweden, had higher nicotine depend-
ence levels compared to those from countries with
higher prevalence of smoking, such as Germany [24].
Healthy persons from United States had higher rates of
heavy nicotine dependence compared to Spanish control
sample [2].
Men had higher smoking prevalence than women, in
European countries including Croatia [26], and unlike
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women, Croatian men did not show decreasing trend in
smoking prevalence [27]. Croatian men also had higher
prevalence of heavy smoking compared to women [28],
which is in line with data from other regions. For ex-
ample, in healthy persons, males had higher FTND total
scores [24, 29], and higher nicotine and cotinine levels
[29] than females. In patients with schizophrenia severe
nicotine dependence was associated with male gender
[30]. Patients with schizophrenia from Spain had higher
smoking prevalence compared to those from Germany,
Greece and Italy [25].
To the best of our knowledge, no study has compared
smoking behavior in Croatian patients with schizophre-
nia and healthy individuals. Given the above gender and
regional differences in smoking indices, and complex re-
lationship between smoking and schizophrenia, more in-
vestigation is needed to verify factors associated with
nicotine dependence in schizophrenia, in different coun-
tries. The aim of the present study was to contribute to
the current knowledge of smoking behavior in schizo-
phrenia, and to investigate smoking behavior in Croatian
patients. Specific objectives were to:
1) compare patterns of nicotine dependence between
patients with schizophrenia and healthy controls
2) determine the pattern between nicotine dependence
and psychopathology in patients with schizophrenia
Methods
Study setting and subjects
This cross-sectional study was carried out in University
Hospital Centre Zagreb, Department of Psychiatry, and
Psychiatric Hospital Popovača. Inclusion criteria were:
male inpatients aged 18 to 65 years, diagnosed with
schizophrenia, who were current smokers. Since daily
smoking is considered to be a sign of nicotine addiction
[25], smokers were defined as individuals who declared
to smoke at least one cigarette daily. Given the observed
differences in smoking patterns observed in both healthy
subjects [24, 29] and individuals with schizophrenia [25,
30] only males were enrolled. Exclusion criteria were:
intellectual disability and other conditions affecting the
current capacity to participate in the evaluation, such as
moderate to severe agitation and/or aggression, catatonic
features, patients with first-episode psychosis, substance
abuse and dependence in the previous year other than
nicotine and caffeine dependence, and any severe and/or
unstable comorbid somatic or neurological disorder. Al-
though subjects with the most severe clinical presenta-
tions were not included because of insufficient
cooperation and understanding of questions and purpose
of the study, there were no cut-off values in overall dis-
ease severity for the exclusion of patients.
Incusion criteria for healthy group were: males who
were daily smokers, and exclusion criteria were: current
or previous psychiatric disorders, comorbid substance
use (other than nicotine and caffeine), as well as somatic
(inclusive neurological) disorders.
Assessment
Diagnosis of schizophrenia was confirmed by the Struc-
tured Clinical Interview (SCID) [31] based on the DSM-
IV criteria (American Psychiatric Association, 1994). The
level of nicotine dependence was measured by the Fager-
strom Test for Nicotine Dependence (FTND) [32],
which is composed of six questions about daily cigarette
consumption. It assesses the extent of cigarette smoking
and smoking behavior. This questionnaire is the most
widely used measure of nicotine dependence [33] and is
also a reliable tool for the assessment of smoking behav-
ior in schizophrenia [34]. Both patients and control
group have fulfilled the FTND. The Cronbach alpha co-
efficients in the healthy and patient group were 0.76 and
0.68, respectively, indicating adequate internal reliability
(having in mind the low number of items comprising
this scale).
Symptom severity in patients was evaluated by struc-
tured interview for PANSS, including the PANSS posi-
tive, PANSS negative, PANSS general psychopathology
subscale [35] and PANSS Cognitive subscale [36]. The
average total score was 114.35 (SD = 21.609).
For this study, participants were divided in three
groups according to the levels of tobaccodependence: (1)
smokers with low dependence (FTND 0–4) (2) smokers
with moderatedependence (FTND = 5) and (3) smokers
with severe dependence (FTND≥6).
The investigation was approved by local Ethics Com-
mittee and was carried out in accordance with the
Helsinki declaration (1975). All patients have signed in-
formed consent approved by Ethics Committee prior to
inclusion. The investigation was a part of a project “Pre-
dictors of treatment response in schizophrenia”, BM1.45,
sponsored by the University of Zagreb.
Statistical analysis
We ran all the statistical analyses in the SPSS version 19
(SPSS, Chicago, IL). Descriptive statistics contained
means (M) and standard deviations (SD). Internal reli-
ability of the FTND was described by Cronbach alpha
coefficients. Mann-Whitney U test, Chi-square test and
independent samples t-test were used to examine the
potential differences in age and tobacco dependence pa-
rameters between schizophrenia patients and healthy
control subjects. Pearson correlations were computed to
examine the zero-order relationship among the investi-
gated variables. The level of statistical significance was
set at P < 0.05.
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Results
Overall, 182 patients and 280 healthy individuals took
part in this investigation. The average length of treat-
ment was 17.49 years (SD = 8.395), while the average
number of previous psychiatric hospitalizations was 5.91
(SD = 4.730).
The average age was 42.20 years (SD = 11.974) for pa-
tients and 40.26 years (SD = 10.250) for healthy partici-
pants. The difference in their average age was not
statistically significant (t = 1.784, df = 436, p = 0.075).
The differences between the groups (patients and
healthy controls) in the total score on the FTND scale,
individual items as well as the three tobacco dependence
categories, are shown in Tables 1 and 2.
As presented in Table 1, patients had significantly higher
total score on the tobacco dependence measure, compared
to healthy subjects. On the individual items, patients
scored higher on items 1 (they tended to smoke their first
cigarette earlier after waking up) and 4 (they smoked more
cigarettes a day). Higher percentage of healthy controls
compared to patients found it harder to refrain from smok-
ing in places where it is forbidden (item 2) and they
smoked more even when they were sick (item 6). No differ-
ences were observed in items 3 and 5.
In addition, based on the chi-square test (χ2 = 6.416, p
< .04) (Table 2) patients were more often categorized as se-
verely dependent on tobacco, whereas healthy controls
were more often in the low dependence category. There
was no difference in the frequencies of moderate depend-
ence category among groups. The exact distribution of pa-
tients and healthy controls in the three nicotine
dependence categories is shown in Table 2.
Finally, there was no significant correlation between
age and FTND total score in both groups, and there
was also no correlation between the PANSS total
score and positive and negative scores with FTND
total score in the patient group (p > 0.05). However,
negative correlations between item 2 on FTND scale
and PANSS total score, as well as PANSS positive
and general subscores, were observed, as presented in
Table 3.
Discussion
Main findings of the present study are:
1) Smokers with schizophrenia had higher FTND score
compared to healthy smokers,
2) Smokers with schizophrenia had higher rates of
severe dependence while healthy smokers had higher
rates of light dependence,
3) On the individual FTND items, patients with
schizophrenia scored higher on items 1 and 4,
healthy individuals scored higher on items 2 and 6,
while there were no significant differences on items
3 and 5.
Severity of nicotine dependence in patients and healthy
controls
We confirmed previous reports of increased FTND
scores in patients with schizophrenia compared to
healthy individuals [34, 37] and increased frequency of
heavy smoking compared with general population [3].
However, our findings disagree with similar prevalence
of heavy smoking and FTND score in healthy persons
and first-episode patients [10], and with even higher
FTND scores in healthy controls [38]. The differences
might be related to age, since the prevalence of smoking
in patients with schizophrenia increases with age [5, 39].
Smokers with schizophrenia were older than non-
smokers [17]. Given the self-medication hypothesis of
smoking in schizophrenia [20], it might be speculated
that older patients smoked more often in order to allevi-
ate extrapyramidal and depressive symptoms, which are
related to longer disease duration [40, 41]. However,
other studies on individuals with schizophrenia have re-
ported that smokers were actually younger than non-
smokers [14, 16]. Because schizophrenia is highly
heterogonous disorder, longitudinal studies are needed
to investigate whether and how the pattern of smoking
changes throughout its course.
The average age in both of our groups corresponds to
age-range which had the highest prevalence of smoking
in European general population [26]. The discrepancy
Table 1 Comparisons between the schizophrenia patients and healthy controls in the investigated tobacco dependence parameters
Schizophrenia patients
(n = 182)
Healthy controls
(n = 280)
U / X2(df) P
FTND total (mean (SD)) 5.60 (2.312) 4.98 (2.690) 21,911 .010
FTND item 1 (mean (SD)) 2.07 (1.044) 1.59 (1.027) 17,951 .000
FTND item 2 (proportions of yes answers) 40.7% 60% 16.542 (1) .000
FTND item 3 (proportions of yes answers) 70.3% 72.1% 0.178 (1) .673
FTND item 4 (mean (SD)) 1.55 (.857) 1.17 (.825) 19,227 .000
FTND item 5 (proportions of yes answers) 47.8% 38.9% 3.556 (1) .060
FTND item 6 (proportions of yes answers) 40.1% 60.7% 18.782 (1) .000
FTND Fagerstrom Test for Nicotine Dependence, U Mann Whitney test, X2(df) Chi-square test and degrees of freedom; Significant P values are highlighted in bold
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with reference [38], might arise from differences in
smoking limitation. While in the latter study there was a
restriction of smoking, in our hospitals there is facility
where patients are allowed to smoke. More smoking re-
strictions might discourage light smokers to consume
cigarettes, but not individuals who are more heavily
dependent [24].
In the present study, compared to healthy individuals,
smokers with schizophrenia had also higher prevalence of
severe, and lower prevalence of mild nicotine dependence.
There is some evidence that severe nicotine dependence
may have distinct biological changes [42, 43]. However,
the present study did not measure biological markers.
Differences in smoking behavior between patients and
healthy individuals
Several differences in smoking behavior were observed
between group of patients and healthy subjects.
Item 1-How soon after you wake up do you smoke your
first cigarette?
Our patients had higher scores on item 1, which has
correlated with a difficulty in maintaining abstinence
due to emerging withdrawal symptoms [44], and was re-
peatedly found related to nicotine dependence in general
population [29], while data on patients with schizophre-
nia are missing. For example, FTND items 1, 4 and 5
were the best predictors of cotinine concentrations in
general population [45]. This item was even proposed to
be a good single-item measure of nicotine dependence
[46]. Therefore, our findings smoking in European genre
severe nicotine dependence in schizophrenia [3], par-
ticularly in males.
Item 2-Do you find it difficult to refrain from smoking in
places where it is forbidden?
While higher inhibition of smoking in patients compared
to control group might appear counterintuitive, this
finding could result from different settings. Our hospital
facilities had smoking areas, and unlike healthy persons,
patients had no smoking restrictions. On the contrary,
smoking ban at workplace was found to decrease both
average number of daily cigarette consumption and pro-
portion of heavy smokers in Croatian healthcare stuff
[47]. While majority of patients were unemployed and
all healthy participants had regular jobs, those two
groups might have been differently affected by smoke-
free laws. Alternatively, higher levels of nicotine depend-
ence were related to lower inhibitory capacity in healthy
persons [48, 49] and individuals with different psychi-
atric conditions [49].
Item 3-Which cigarette do you hate most to give up?
This item, which differentiates first morning cigarette
from any other during the day, had similar scores in pa-
tients and controls. It is another FTND item focusing on
morning smoking as an indicator of greater nicotine de-
pendence, which is related to the preference of first
cigarette in the morning. Some authors have raised con-
cern that FTND may deflate nicotine dependence scores
among smokers with schizophrenia [33]. Differences in
restrictions to smoking between patients and controls
also need to be taken into account in the interpretation
of this finding.
Item 4. The number of cigarettes, smoked per day
This item, together with item 1, is supposed to reflect
the best nicotine dependence. The sum of those 2 items
is referred to as the heaviness of smoking index [3, 50],
and had the greatest impact on exposure to nicotine and
carbon monoxide [51]. Patients in the present study had
higher scores in both items 1 and 4, which is consistent
with meta-analysis that patients with schizophrenia
smoke “heavier” than smokers in general population [3]
and with other reports of higher number of cigarettes
smoked daily in patients in first-episode psychosis [52]
and schizophrenia [53].
Item 5. Do you smoke more frequently during the first
hours after awakening than during the rest of the day?
No differences were found between groups on the item
5 score. Since both items 3 and 5 refer to higher priority
of morning smoking compared to the rest of the day,
both groups appear to have had similar levels of
Table 2 Frequencies of schizophrenia patients and healthy
controls in the three tobacco dependence categories
Mild tobacco
dependence
Moderate tobacco
dependence
Severe tobacco
dependence
Patients with
schizophrenia
58 (31.9%) 25 (13.7%) 99 (54.4%)
Healthy controls 119 (42.5%) 41 (14.6%) 120 (42.9%)
Chi-square test (X2) = 6.416; df = 2; p = 0.041
Table 3 Pearson correlations between FTND scores and values
on the PANSS diagnostic scale
Variables PANSS – total PANSS – P PANS S –N PANSS – G
FTND 1 .04 .02 .04 .04
FTND 2 −.18* −.17* −.13 −.16*
FTND 3 −.03 −.09 .04 −.02
FTND 4 −.02 .05 −.04 −.06
FTND 5 −.08 −.09 −.09 −.03
FTND 6 −.02 .02 −.04 −.02
FTND total −.06 −.05 −.04 −.05
FTND Fagerstrom Test for Nicotine Dependence, PANSS Positive and Negative
Syndrome Scale P positive symptoms subscale, N negative symptoms subscale,
G general psychopathology subscale
*statistically significant correlations (P < = .036)
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morning cigarette craving. Smokers with schizophrenia,
however, use tobacco during the night, and therefore
may maintain sufficient nicotine levels to suppress
morning withdrawal symptoms [33]. Although the
current study did not measure nighttime smoking, simi-
lar scores in items 3 and 5 might simply reflect less noc-
turnal smoking in healthy individuals.
Item 6. Do you smoke even if you are so ill that you are
in bed most of the day?
This item addresses persistence in maintaining nicotine
concentrations during waking hours. In the present
study, healthy persons scored higher on FTND items re-
lated to difficulties in restraining from smoking at cer-
tain places (item 2) and situations (item 6). It might be
that, unlike healthy smokers, smokers with schizophre-
nia do not even attempt to refrain from smoking. In fact,
patients with schizophrenia had impaired impulse con-
trol compared to healthy persons [54], and among pa-
tients, smokers exhibited even higher rates of
impulsivity [55] and had different motives to smoke,
such as “increased need of stimulation” and lower scores
of “sociability” [56]. Therefore, variations in impulse
control and motivation for smoking might help explain
the higher score on items 2 and 6 in healthy controls.
Nicotine dependence and severity of symptoms
We observed no associations between smoking severity
and PANSS total score and any of its subscales or indi-
vidual items. Those findings contrast previous reports of
lower negative symptom severity in patients with higher
levels of nicotine dependence [57–60] and positive cor-
relations between FTND and PANSS negative scale, and
several PANSS general items [61]. Our results are in line
with other authors who observed no correlations be-
tween FTND total score [38], presence of severe nicotine
dependence [30] and number of cigarettes per day [10],
with any of PANSS items.
Those discrepancies might arise from disease severity,
patient age, definitions of severity of nicotine depend-
ence and comorbidity. Patients in majority of studies
had the average PANSS total score lower than 60 [57–
59], 80 [10, 30, 38], and 82 [60]. Our patients had more
severe clinical presentation, as reflected by their PANSS
total score of 114. The only study that also included
acutely psychotic patients, with an average PANSS score
of 105 [61], reported a positive correlation between
FTND and PANSS negative scale, and items of unusual
thought content, disorientation, poor attention, and poor
impulse control [61]. While all those studies, including
the current one, were cross-sectional, longitudinal stud-
ies are needed to determine whether the association be-
tween heaviness of smoking and severity of symptoms
changes during phases of illness.
Another explanation might include gender, given that
men had higher nicotine dependence in healthy individ-
uals [24, 29] and in patients with schizophrenia [30], and
other addictions. While cannabis and alcohol consump-
tion were related to more positive symptoms [62, 63],
and less prominent negative symptoms [62], those co-
morbidities might also influence severity of symptoms
and contribute to discrepant findings. The definition of
heavy smoking has also varied across studies. For ex-
ample, [58] defined heavy smokers as those who smoked
at least one pack of cigarettes per day, while we used
FTND definition.
Limitations
Due to cross-sectional design, causal relationship cannot
be established. Groups were not controlled for other var-
iables, such as education, financial status, and doses of
antipsychotics. Smoking data were based on self-report
and, given that patients were acutely psychotic, results
might not be completely accurate. Given that PANSS
rating was performed by 5 psychiatrists, who were in
most cases also treating psychiatrists for those patients,
potential bias cannot be excluded. In addition, given
than only men without recent substance abuse were in-
cluded, those findings might not be generalizable to
women and / or patients with current substance abuse.
Another limitation is that sociodemographic data for
healthy control group were not collected.
Conclusions
Our results extend previous findings of higher levels of
nicotine dependence in patients with schizophrenia
compared to healthy persons, to patients from Croatia,
according to the hypothesis [25] that “schizophrenia is
associated with increased smoking among smokers”.
Our findings also highlight the differences in their smok-
ing behavior compared to healthy smokers. In spite of
those variations, degree of nicotine dependence was not
associated with the severity of the disease or any particu-
lar symptoms. Given the high prevalence of both smok-
ing and severe nicotine dependence in patients with
schizophrenia, future investigations comparing smoking
behavior in remitted patients versus those in acute re-
lapse are needed.
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